These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33783712)

  • 41. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
    Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced Retinal Microvascular Density Related to Activity Status and Serum Antibodies in Patients with Graves' Ophthalmopathy.
    Wu Y; Tu Y; Bao L; Wu C; Zheng J; Wang J; Lu F; Shen M; Chen Q
    Curr Eye Res; 2020 May; 45(5):576-584. PubMed ID: 31595798
    [No Abstract]   [Full Text] [Related]  

  • 43. Evaluation of the Effect of Proptosis on Choroidal Thickness in Graves' Ophthalmopathy.
    Yıldırım G; Şahlı E; Alp MN
    Turk J Ophthalmol; 2020 Aug; 50(4):221-227. PubMed ID: 32854466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
    Li HX; Xiang N; Hu WK; Jiao XL
    J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
    De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
    Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients.
    Li J; Xiao Z; Hu X; Li Y; Zhang X; Zhang S; Gong W; Zhao J; Ye X
    Pharmacology; 2017; 99(3-4):144-152. PubMed ID: 28049190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New immunomodulators in treatment of Graves'ophtalmopathy].
    Josseaume C; Lorcy Y
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S29-32. PubMed ID: 18954856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
    Nielsen CH; El Fassi D; Hasselbalch HC; Bendtzen K; Hegedüs L
    Expert Opin Biol Ther; 2007 Jul; 7(7):1061-78. PubMed ID: 17665994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the patients with Grave's ophthalmopathy after the corticosteroids treatment.
    Petrović MJ; Sarenac T; Srećković S; Petrović M; Vulović D; Janićijević K
    Vojnosanit Pregl; 2012 Mar; 69(3):249-52. PubMed ID: 22624411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials.
    Lin F; Yao Q; Yu B; Deng Z; Qiu J; He R
    Int J Clin Pract; 2023; 2023():6638089. PubMed ID: 37588100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of rituximab in treating steroid-resistant Graves' orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China.
    Zhang Z; Feng X; Guo Y; Kang X; Wang D; Zhang J; Zeng Z; Yuan G
    Heliyon; 2024 Jun; 10(11):e31932. PubMed ID: 38867959
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
    Gerding MN; van der Meer JW; Broenink M; Bakker O; Wiersinga WM; Prummel MF
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):267-71. PubMed ID: 10718823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy.
    Hiromatsu Y; Eguchi H; Matsuo Y; Kato T; Tani J; Watanabe S; Teshima Y; Araki N
    Endocr J; 2020 Mar; 67(3):347-352. PubMed ID: 31827052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.
    Ma Z; Ozaki H; Ishikawa Y; Jingu K
    Jpn J Radiol; 2019 Aug; 37(8):612-618. PubMed ID: 31201593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Short-term efficacies of intravenous glucocorticoid therapy for moderate-to-severe Graves' ophthalmopathy].
    Guo L; Yang G; Gu W; Jin N; Chen K; Du J; Wang X; Ouyang J; Dou J; Ba J; Lü Z; Mu Y
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(20):1572-5. PubMed ID: 26463604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
    Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
    Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients.
    Ahn HY; Lee JK
    J Korean Med Sci; 2020 Jun; 35(23):e177. PubMed ID: 32537950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum levels of soluble Fas in patients with Graves' ophthalmopathy.
    Ohtsuka K; Hashimoto M
    Br J Ophthalmol; 2000 Jan; 84(1):103-6. PubMed ID: 10611108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.